Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Arshdeep Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India. Hauptthemen laut MEDLINE: Piperidines, Colitis, Ulcerative, Pyrimidines, Azathioprine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
The optimal maintenance therapy for patients with acute severe ulcerative colitis (ASUC) remains unclear.
Aim
To evaluate the efficacy of azathioprine and tofacitinib in maintaining remission in patients with ASUC who respond to intravenous corticosteroids.
Methods
This propensity score–matched, retrospective cohort study evaluated the effectiveness and safety of azathioprine and tofacitinib as maintenance therapies in adult patients with ASUC responding to intravenous corticosteroids. We recorded rehospitalisation, corticosteroid reuse, therapeutic escalation, and colectomy. The primary endpoint was cumulative event‐free survival at 1 year. Adverse events were documented in both treatment arms.
Results
We included 115 patients in the final analysis (median age: 38 years [IQR: 28–49]; 54 females [46.95%]; 65 on azathioprine, 50 on tofacitinib). The cumulative probability of event‐free survival at 1 year was 44.0% with azathioprine and 75.0% with tofacitinib (log‐rank p = 0.01). Rates of rehospitalisation (15.4% v. 0%; p = 0.003) and therapeutic escalation (13.8% v. 2.0%; p = 0.02) were significantly greater in the azathioprine group. More patients receiving tofacitinib achieved symptomatic remission (40.0% v. 23.1%; p = 0.05), and combined symptomatic and biomarker remission (22.0% v. 16.9%; p = 0.49) at 1 year than those receiving azathioprine. Adverse events were reported in 55 patients (47.8%). No patients in either group required discontinuation of therapy due to adverse events.
Conclusion
Tofacitinib is more effective than azathioprine as maintenance therapy for steroid‐responsive ASUC at 1 year.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
- Research Associate, Digestive Diseases Care Foundation, Ludhiana, India.
- Research and Development Centre, Dayanand Medical College and Hospital, Ludhiana, India.
- Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India.
ORCID-Profile: Arshdeep Singh
Zitieren
APA
Singh, A., Bhardwaj, A., Sharma, R., Singh, D., Jain, D., Bansal, N., Kochhar, G. S., Midha, V., & Sood, A. (2025). Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70246
Vancouver
Singh A, Bhardwaj A, Sharma R, Singh D, Jain D, Bansal N, et al. Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70246
BibTeX
@article{Singh2025,
author = {Singh, Arshdeep and Bhardwaj, Arshia and Sharma, Riya and Singh, Dharmatma and Jain, Devanshi and Bansal, Namita and Kochhar, Gursimran Singh and Midha, Vandana and Sood, Ajit},
title = {Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70246}
}
EUVIMED